TY - GEN
T1 - Highly sensitive fluorescence-based lateral flow platform for point-of-care detection of biomarkers in plasma
AU - Zhu, Meilin
AU - Obahiagbon, Uwadiae
AU - Anderson, Karen
AU - Blain Christen, Jennifer
N1 - Funding Information:
Meilin Zhu was sponsored by the SenSIP REU, supported in part by NSF Award 1659871. This work was supported by the National Science Foundation Smart and Connected Health [grant number IIS-1521904] SCH:INT:‘Disposable
Funding Information:
Meilin Zhu was sponsored by the SenSIP REU, supported in part by NSF Award 1659871. This work was supported by the National Science Foundation Smart and Connected Health [grant number IIS-1521904] SCH:INT:'Disposable high sensitivity point of care immunosensor for multiple disease and pathogen detection and the National Cancer Institute Cancer Detection, Diagnosis, and Treatment Technologies for Global Health [grant number CA211415] Rapid Point-of-Care Detection of HPV-associated Malignancies.
Publisher Copyright:
© 2017 IEEE.
PY - 2017/12/19
Y1 - 2017/12/19
N2 - Point-of-Care (PoC) diagnostic devices, such as lateral flow tests, are often used in low and middle-income countries (LMIC) for low-cost disease detection. Most commercial lateral flow tests use colorimetric detection on a nitrocellulose substrate. In this paper, we present a multistep, fluorescence-based assay detection system, which can detect antibodies in plasma to recombinant protein. Fluorescence-based detection allows us to achieve higher sensitivity, while a nitrocellulose substrate enables fluid handling, high protein immobilization, rapid detection time, and affordability. As a proof-of-concept for detection of disease-specific biomarkers in plasma, we demonstrate the detection of antibodies in plasma to Epstein-Barr nuclear antigen-1 (EBNA-1) recombinant protein and to human papillomavirus (HPV) 16 E7 recombinant protein. We show that our detection system is able to detect EBNA-1-specific antibodies at a 1:10,000 plasma dilution and HPV 16 E7-specific antibodies at a 1:5,000 plasma dilution, indicating high sensitivity. This platform is a low-cost device that can detect fluorescence from labeled biomarkers on a lateral flow assay. Ultimately, we aim to adapt this system to detect HPV 16 and 18 biomarkers for cervical cancer screening in LMICs.
AB - Point-of-Care (PoC) diagnostic devices, such as lateral flow tests, are often used in low and middle-income countries (LMIC) for low-cost disease detection. Most commercial lateral flow tests use colorimetric detection on a nitrocellulose substrate. In this paper, we present a multistep, fluorescence-based assay detection system, which can detect antibodies in plasma to recombinant protein. Fluorescence-based detection allows us to achieve higher sensitivity, while a nitrocellulose substrate enables fluid handling, high protein immobilization, rapid detection time, and affordability. As a proof-of-concept for detection of disease-specific biomarkers in plasma, we demonstrate the detection of antibodies in plasma to Epstein-Barr nuclear antigen-1 (EBNA-1) recombinant protein and to human papillomavirus (HPV) 16 E7 recombinant protein. We show that our detection system is able to detect EBNA-1-specific antibodies at a 1:10,000 plasma dilution and HPV 16 E7-specific antibodies at a 1:5,000 plasma dilution, indicating high sensitivity. This platform is a low-cost device that can detect fluorescence from labeled biomarkers on a lateral flow assay. Ultimately, we aim to adapt this system to detect HPV 16 and 18 biomarkers for cervical cancer screening in LMICs.
UR - http://www.scopus.com/inward/record.url?scp=85048486049&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048486049&partnerID=8YFLogxK
U2 - 10.1109/HIC.2017.8227631
DO - 10.1109/HIC.2017.8227631
M3 - Conference contribution
AN - SCOPUS:85048486049
T3 - 2017 IEEE Healthcare Innovations and Point of Care Technologies, HI-POCT 2017
SP - 249
EP - 252
BT - 2017 IEEE Healthcare Innovations and Point of Care Technologies, HI-POCT 2017
PB - Institute of Electrical and Electronics Engineers Inc.
T2 - 2017 IEEE Healthcare Innovations and Point of Care Technologies, HI-POCT 2017
Y2 - 6 November 2017 through 8 November 2017
ER -